Semarion secures £2.9M to accelerate drug discovery workflows
UK-based biotech startup Semarion has raised £2.9 million in fresh funding to scale its next-generation cell assay platform, designed to make early-stage drug discovery faster, more reliable and more cost-efficient.
The round was led by university spinout specialist investor Parkwalk, with participation from existing and new backers focused on life sciences innovation. The capital injection will be used to expand commercial operations, deepen R&D and drive adoption of Semarion’s proprietary SemaCyte technology across pharma and biotech pipelines.
Transforming cell assays with SemaCyte microcarriers
Semarion’s platform tackles a long-standing bottleneck in preclinical research: the difficulty of handling and measuring living cells at scale. Traditional cell assays are often slow, variable and labour-intensive, limiting how quickly researchers can screen and validate new drug candidates.
The company’s SemaCyte system uses advanced microcarrier technology to anchor and manipulate cells more precisely on standard lab equipment. By improving cell stability, positioning and readout quality, the platform aims to reduce experimental noise and enable higher-throughput screening without sacrificing biological relevance.
For pharmaceutical researchers, this promises more predictive data earlier in the pipeline, helping to identify promising compounds sooner and discard weak candidates before they absorb significant time and budget.
Backing from deep-tech and life sciences investors
Parkwalk, a leading investor in UK university spinouts, is backing Semarion as part of a broader thesis around enabling technologies for precision medicine and drug discovery platforms. The fund’s support is expected to help Semarion deepen collaborations with academic partners and large pharma companies.
The new funding will allow Semarion to scale manufacturing of SemaCyte consumables, expand its scientific and commercial teams, and validate the platform across a wider range of cell types and disease models. As competition intensifies to shorten development timelines and lower attrition rates, robust and scalable cell-based assays are becoming a strategic priority for the global biopharma industry.
By focusing on the underlying tools that power discovery, Semarion is positioning itself as an enabling player in the next wave of data-rich, biology-first drug development.